A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation

[1]  Helge G. Roider,et al.  Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses , 2023, Clinical and experimental medicine.

[2]  Yanfang Zhao,et al.  Design and Synthesis of 1,3,5-Triazines or Pyrimidines Containing Dithiocarbamate Moiety as PI3Kα Selective Inhibitors. , 2023, ACS medicinal chemistry letters.

[3]  Ralitsa R. Madsen,et al.  A small molecule PI3Kα activator for cardioprotection and neuroregeneration , 2023, Nature.

[4]  O. Cohen,et al.  Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer , 2023, Science advances.

[5]  G. Freeman,et al.  PI3Kβ controls immune evasion in PTEN-deficient breast tumours , 2023, Nature.

[6]  M. Elkabets,et al.  TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer , 2023, bioRxiv.

[7]  M. Elkabets,et al.  Stellettin B Sensitizes Glioblastoma to DNA‐Damaging Treatments by Suppressing PI3K‐Mediated Homologous Recombination Repair , 2022, Advanced science.

[8]  J. Chandrasekhar,et al.  Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors. , 2022, Accounts of chemical research.

[9]  L. Cantley,et al.  At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy , 2022, Nature Reviews Clinical Oncology.

[10]  L. Qin,et al.  The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma , 2022, Cellular & Molecular Immunology.

[11]  John G Doench,et al.  PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment , 2022, Journal for ImmunoTherapy of Cancer.

[12]  Jae-Sung Kim,et al.  PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation , 2022, Journal for ImmunoTherapy of Cancer.

[13]  Ningshu Liu,et al.  Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment , 2022, Nature Communications.

[14]  G. Sonpavde,et al.  Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer , 2021, Journal for ImmunoTherapy of Cancer.

[15]  Y. Carmi,et al.  MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer , 2021, Journal for ImmunoTherapy of Cancer.

[16]  G. Zhuang,et al.  USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade , 2021, Nature Communications.

[17]  S. Dan,et al.  Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal , 2021, Journal for ImmunoTherapy of Cancer.

[18]  Jian Ding,et al.  PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism , 2021, Journal for ImmunoTherapy of Cancer.

[19]  Zhe-Sheng Chen,et al.  Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy , 2021, Journal of Experimental & Clinical Cancer Research.

[20]  K. Okkenhaug,et al.  PI3K inhibitors are finally coming of age , 2021, Nature Reviews Drug Discovery.

[21]  J. Engelman,et al.  The present and future of PI3K inhibitors for cancer therapy , 2021, Nature Cancer.

[22]  M. Elkabets,et al.  BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair , 2021, Cell Death & Disease.

[23]  R. Sullivan,et al.  Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  T. Mak,et al.  Beyond immune checkpoint blockade: emerging immunological strategies , 2021, Nature Reviews Drug Discovery.

[25]  J. Larkin,et al.  Enhancing anti-tumour efficacy with immunotherapy combinations , 2020, The Lancet.

[26]  Reem Saleh,et al.  Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. , 2020, Seminars in cancer biology.

[27]  Chao Lu,et al.  PIK3CA and p53 Mutations Promote 4NQO-Initated Head and Neck Tumor Progression and Metastasis in Mice , 2020, Molecular Cancer Research.

[28]  G. Lenz,et al.  Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study , 2019, American journal of hematology.

[29]  C. Arteaga,et al.  Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. , 2019, Cancer discovery.

[30]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[31]  K. Okkenhaug,et al.  Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. , 2018, JCI Insight.

[32]  F. Meric-Bernstam,et al.  Targeting the PI3K pathway in cancer: are we making headway? , 2018, Nature Reviews Clinical Oncology.

[33]  S. Loi,et al.  Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. , 2017, Cancer research.

[34]  A. Markham.  Copanlisib: First Global Approval , 2017, Drugs.

[35]  T. Strom,et al.  Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ , 2017, Nature Communications.

[36]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[37]  Andrew C Johnson,et al.  PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses , 2016, Clinical Cancer Research.

[38]  J. Kutok,et al.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.

[39]  A. V. Nguyen,et al.  Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. , 2016, Cancer discovery.

[40]  Dexin Kong,et al.  Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy , 2016, Acta pharmaceutica Sinica. B.

[41]  K. Cornille,et al.  Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition , 2016, Breast Cancer Research.

[42]  J. Baselga,et al.  Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors , 2016, Clinical Cancer Research.

[43]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[44]  D. Gao,et al.  microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma , 2015, Journal of Hematology & Oncology.

[45]  Angela Tam,et al.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.

[46]  J. Engelman,et al.  Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. , 2015, Cancer cell.

[47]  Simon T Barry,et al.  Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. , 2015, Cancer cell.

[48]  S. Dan,et al.  In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA , 2014, Investigational New Drugs.

[49]  Dalya R. Soond,et al.  Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer , 2014, Nature.

[50]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[51]  X. Mao,et al.  Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization , 2014, Journal of Hematology & Oncology.

[52]  N. Rosen,et al.  mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer , 2013, Science Translational Medicine.

[53]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[54]  Dexin Kong,et al.  JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. , 2012, Bioorganic & medicinal chemistry.

[55]  P. Hawkins,et al.  PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.

[56]  A. Luster,et al.  CXCR3 in T cell function. , 2011, Experimental cell research.

[57]  J. Tabernero,et al.  Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.

[58]  T. Yamori,et al.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system , 2010, Acta Pharmacologica Sinica.

[59]  S. Dan,et al.  Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. , 2010, European journal of cancer.

[60]  Dexin Kong,et al.  ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms , 2007, Cancer science.

[61]  K. Okkenhaug,et al.  PI3K in lymphocyte development, differentiation and activation , 2003, Nature Reviews Immunology.

[62]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[63]  E. Bröcker,et al.  Strong expression of the lymphoattractant C‐X‐C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma , 1999, The Journal of pathology.